ALPROLIX^®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE^1–3

PROVEN BLEED PROTECTION
IN A COUNTRY-WIDE SWITCH⁶

In a four-year retrospective study (two years pre-switch and two years
post-switch), all patients with haemophilia B in Ireland (N=28) were
switched from SHL FIX (on-demand or prophylaxis) to ALPROLIX prophylaxis, reporting:⁶

Improved ABRs⁶

Median ABRs improved with ALPROLIX vs pre-switch SHL FIX⁶

ABR pre-switch and 12–24 months post-switch to ALPROLIX⁶

Adapted from O'Donovan M, et al. 2021.⁶

Reduced joint bleeds⁶

Joint bleeds significantly reduced with ALPROLIX vs
pre-switch SHL FIX⁶

• Mean AjBR with SHL FIX (on-demand treatment and prophylaxis) was 3.9, reducing to 2.1 (p=0.05) following 24 months of ALPROLIX prophylaxis (n=23 [available data])⁶

Increased proportion of patients with zero bleeds⁶

14%

numerical increase in patients
experiencing zero bleeds

12–24 months after switching from SHL FIX 18% (5/28) vs. 4% (1/28)⁶

*Includes patients previously treated with on-demand (n=6) and prophylactic SHL FIX (n=22) at the point of switchover. Two patients were treated on-demand and with prophylaxis for differing time periods in the two years prior to switchover.⁶
ABR, annualised bleeding rate; AjBR, annualised joint bleeding rate; FIX, factor IX; SHL, standard half-life.

REDUCED INJECTION BURDEN VS SHL FIX
IN A COUNTRY-WIDE SWITCH⁶

Reduced weekly injection frequency⁶

Prophylaxis injection frequency pre-switch vs post-switch*⁶

Adapted from O’Donovan M, et al. 2021.⁶

Reduced factor consumption⁶

28% reduction in weekly median FIX consumption with ALPROLIX prophylaxis vs SHL FIX prophylaxis⁶

Reduced yearly injection frequency⁶

Most patients halved the number of injections
per year with ALPROLIX

52 vs 104 injections^‡6

*Percentages have been rounded to whole numbers; non-rounded values add up to 100.^{6 †}At the time of switchover to ALPROLIX, 21% (n=6/28) of patients were receiving on-demand SHL FIX and 79% (n=22/28) were on prophylaxis with SHL FIX.^{6 ‡}Calculated from dosing schedules pre- and post-switch. Most patients on prophylaxis with SHL FIX were on twice-weekly injections (n=19/22).⁶
FIX, factor IX; SHL, standard half-life.

IMPROVED ACTIVITY-RELATED PAIN VS SHL FIX⁷

*The PROBE questionnaire has four domains: demographics, general health, haemophilia-specific, and European Quality of Life 5-Dimensions (EQ-5D-5L) questionnaire.⁷
FIX, factor IX; SHL, standard half-life.

PROVEN BLEED PROTECTION
IN A COUNTRY-WIDE SWITCH⁶

In 2017, all patients with severe haemophilia B in Ireland switched from SHL FIX (on-demand and prophylaxis) to ALPROLIX prophylaxis as a result of a national tender process⁶

Data were collected retrospectively for a 4-year period from electronic diaries and medical records, including the 2-year period before switching from SHL FIX to determine the patient’s baseline, and the two-year period with ALPROLIX.⁶

*N=31 were eligible but n=28 included in final analysis.^{6 †}Defined as endogenous FIX levels <0.01 IU/mL.^{6 ‡}ABR was calculated based on data for two years on SHL FIX treatment prior to switchover to determine baseline ABR, and for Year 1 and Year 2 of ALPROLIX prophylaxis.⁶
ABR, annualised bleeding rate; AjBR, annualised joint bleeding rate; FIX, factor IX; SHL, standard half-life.

No safety data were collected.⁶